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Purpose: The factors that predict prostate cancer detection on repeat biopsy were eval-
uated in patients with atypical small acinar proliferation (ASAP) on the initial biopsy.
Materials and Methods: From 2003 to 2008, 3,130 men with suspected prostate cancer 
underwent a prostate needle biopsy, and 244 (7.8%) were diagnosed as having ASAP. 
One hundred seventy of 244 patients were rebiopsied at least once more. They were 
classified into a prostate cancer group and a noncancer group according to the final 
pathological diagnosis. The database of rebiopsied patients included age, initial pros-
tate-specific antigen (PSA), PSA density (PSAD), PSA velocity (PSAV), total prostate 
volume (TPV), and transitional zone volume of the prostate (TZV). We compared differ-
ences in the aforementioned parameters between the 2 groups.
Results: A total of 57 patients (33.5%) with ASAP were ultimately shown to have pros-
tate cancer. Univariate analysis showed that PSAD (p=0.002), PSAV (p=0.001), TPV 
(p=0.035), and TZV (p=0.005) differed significantly between the cancer and noncancer 
groups. The results of the multivariate analysis showed that PSAD (p=0.022), PSAV 
(p＜0.001), and TPV (p=0.037) had a statistically significant correlation with cancer 
detection.
Conclusions: PSAD, PSAV, and TPV are predictive factors of prostate cancer in patients 
with an initial diagnosis of ASAP of the prostate. Although repeat biopsy is mandatory 
irrespective of PSA values, the follow-up of PSA may help to estimate the probability 
of cancer in these men.
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INTRODUCTION
Prostate cancer is usually diagnosed by means of trans-
rectal ultrasound (TRUS)-guided needle biopsy. Tissue 
samples simply and clearly indicate the presence or ab-
sence of cancer, but may contain other histological aspects, 
such as nodular hyperplasia (so-called benign prostatic hy-
perplasia, or BPH), prostatitis, atrophy, adenosis, prostate 
intraepithelial neoplasia (PIN, which is distinguished as 
low-grade PIN, or LGPIN, and high-grade PIN, or HGPIN), 
and atypical small acinar proliferation (ASAP) [1,2]. ASAP 
is commonly regarded as atypical foci suspicious but not di-
agnostic of malignancy. Several studies have demonstrated 
that this diagnosis is predictive of malignancy in a sub-
sequent biopsy specimen in 34% to 60% of cases [3,4]. Con-
sequently, a repeat biopsy is recommended in cases of an 
initial ASAP diagnosis.
　The evidence for predictors of prostate cancer after an in-
itial diagnosis of ASAP is contradictory and uncertain. 
Some authors have reported that no clinical or pathological 
findings can increase the accuracy of prediction of cancer 
[5,6]. However, several studies have shown various param-
eters as predictive factors in prostate cancer detection 
[1,7-9]. Hence, we evaluated the clinical factors that pre-Korean J Urol 2010;51:752-756
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TABLE 1. Characteristics of rebiopsied patients (n=170)
Mean (range)
Age (yr) 74.0 (58-85)
Initial PSA (ng/ml) 10.7 (1.4-89.9)
PSAD (ng/ml/ml) 0.30 (0.03-2.75)
PSAV (ng/ml/year)
a 2.8 (−77.0-453.2)
TPV (ml)     39.6 (12.6-133.8)
TZV (ml) 19.6 (4.2-99.0)
PSA: prostate-specific antigen, PSAD: PSA density, PSAV: PSA ve-
locity, TPV: total prostate volume, TZV: transitional zone volume
of the prostate, 
a: PSAV was known for 155 of the total 170 patients.
TABLE 2. Several parameters in rebiopsied patients (with results of Mann-Whitney U test)
Variables
Mean (95% CI for mean)
p-value
Noncancer group (n=113) Cancer group (n=57)
Age (yr) 73.7 (72.5-75.0) 74.6 (73.0-76.3) 0.478
Initial PSA (ng/ml) 9.9 (7.9-11.9) 12.2 (8.7-15.7) 0.159
PSAD (ng/ml/ml) 0.27 (0.21-0.33) 0.36 (0.28-0.44) 0.002
PSAV (ng/ml/year)
a −2.2 (−4.3-0.0) 12.7 (−5.0-30.3) 0.001
TPV (ml) 41.6 (37.6-45.5) 35.7 (32.2-39.1) 0.035
TZV (ml) 21.5 (18.2-24.7) 16.0 (13.0-19.1) 0.005
CI: confidence interval, PSA: prostate-specific antigen, PSAD: PSA density, PSAV: PSA velocity, TPV: total prostate volume, TZV: tran-
sitional zone volume of the prostate, 
a: PSAV was known for 155 of the total 170 patients.
dicted the detection of prostate cancer at rebiopsy.
MATERIALS AND METHODS
From January 2003 to December 2008, 3,130 men under-
went a TRUS-guided (IU-22; Philips, Andover, MA, USA) 
prostate biopsy with an 18-gauge needle biopsy gun 
(Acecut; TSK Laboratory, Tochigi, Japan) at our in-
stitution, and 244 (7.8%) were diagnosed as having ASAP. 
We advised men with ASAP to undergo rebiopsy within 3 
to 6 months, irrespective of follow-up prostate-specific anti-
gen (PSA) values. Of 244 cases of ASAP, 170 patients had 
at least one more repeat biopsy; the other 74 had no further 
biopsy at our institution owing to patient preference, con-
current prostate cancer, concomitant morbidities, or loss 
to follow-up. Rebiopsied patients were classified into a 
prostate cancer group and a noncancer group according to 
final pathological diagnosis. We categorized one patient 
with ASAP as the final diagnosis (all results for 4 consec-
utive rebiopsies were ASAP) in the noncancer group. We 
retrospectively reviewed our database to obtain age, initial 
PSA, PSA density (PSAD), PSA velocity (PSAV), total pros-
tate volume (TPV), and transitional zone volume of the 
prostate (TZV) in all 170 patients.
　Prostate volume was calculated by the formula 0.523x 
transverse diameter x anteroposterior diameter x longi-
tudinal diameter measured by TRUS. The number of needle 
biopsies was 6 cores in patients with TPV less than 30 ml 
and 12 cores in patients with TPV of 30 ml or more. Immu-
nostains with high molecular weight cytokeratin (34βE12) 
and p63 were added to initial H&E stains. Each histologic 
slide was reviewed by a single experienced pathologist.
　Univariate analysis (Mann-Whitney U test) was per-
formed to compare the clinical patterns of cancer patients 
with those of the noncancer group at rebiopsy. Multivariate 
logistic regression analysis was used to identify any corre-
lation between the detection rate of prostate cancer and the 
previously mentioned factors, with control for potentially 
confounding factors. A value of p＜0.05 was considered 
statistically significant. All data analyses were performed 
by using SPSS ver. 15.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
The mean age of the 170 patients was 74.0 years (range, 
58-85 years), the mean initial PSA value was 10.7 ng/ml 
(range, 1.4-89.9 ng/ml), the mean PSAD was 0.30 ng/ml/ml 
(range, 0.03-2.75 ng/ml/ml), the mean TPV was 39.6 ml 
(range, 12.6-133.8 ml), and the mean TZV was 19.6 ml 
(range, 4.2-99.0 ml). The PSAV was known for 155 of the 
total 170 patients; the mean PSAV of these 155 men was 
2.8 ng/ml/year (range, −77.0-453.2 ng/ml/year) (Table 1).
　A total of 57 patients (33.5%) with ASAP were ultimately 
diagnosed with prostate cancer. The cancer detection rates 
of the 1st, 2nd, 3rd, and 4th repeat biopsy were 24.1% (41/170), 
34.1% (14/41), 18.2% (2/11), and 0% (0/2), respectively.
　In 57 patients with a final diagnosis of prostate cancer, 
the mean age was 74.6 years, the mean initial PSA was 12.2 
ng/ml, the mean PSAD was 0.36 ng/ml/ml, the mean PSAV 
was 12.7 ng/ml/year, the mean TPV was 35.7 ml, and the 
mean TZV was 16.0 ml. In 113 patients with no cancer, the 
mean age, mean initial PSA, mean PSAD, mean PSAV, 
mean TPV, and mean TZV were 73.7 years, 9.9 ng/ml, 0.27 
ng/ml/ml, −2.2 ng/ml/year, 41.6 ml, and 21.5 ml, respec-
tively (Table 2). Univariate analysis showed that PSAD (p= 
0.002), PSAV (p=0.001), TPV (p=0.035), and TZV (p=0.005) 
differed significantly between the prostate cancer and non-
cancer groups (Table 2). The results of the multivariate 
analysis showed that PSAD (p=0.022), PSAV (p＜0.001), 
and TPV (p=0.037) had a statistically significant correla-
tion with cancer detection (Table 3).Korean J Urol 2010;51:752-756
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TABLE 3. Results of the multivariate logistic regression analysis
a
Variables p-value
Age 0.165
Initial PSA 0.133
PSAD 0.022
PSAV ＜0.001
TPV 0.037
TZV 0.066
PSA: prostate-specific antigen, PSAD: PSA density, PSAV: PSA
velocity, TPV: total prostate volume, TZV: transitional zone vol-
ume of the prostate, 
a: multivariate analysis was performed for 155
patients because PSAV was known for only 155 of the total 170
men.
DISCUSSION
ASAP has been described by several terms, but today, path-
ologists commonly adopt ASAP or ‘atypical foci suspicious 
but not diagnostic of malignancy’ to define a diagnostic cat-
egory including a broad group of entities [1]. ASAP is not 
a single entity, but rather encompasses a diverse array of 
lesions such as benign crowded glands, basal cell hyper-
plasia, adenosis, reactive atypia, and atypical glandular 
proliferations suspicious for carcinoma, which cannot be 
accurately diagnosed for various reasons such as in-
sufficient amount of specimen or biopsy-induced mechan-
ical distortion [10,11]. Iczkowski mentioned that biopsy 
cores meriting an ASAP diagnosis fall into 2 broad catego-
ries: (i) Qualitatively inadequate cytoarchitectural features. 
A focus may contain about a dozen acini showing such fea-
tures as probable loss of the basal cell layer and infiltrative 
pattern but with a continuum of cytologic features that fall 
short of the cytologic and histologic criteria for cancer. (ii) 
Quantitatively minute linear extent or very few acini. The 
acini in the focus display cytoarchitectural findings com-
patible with cancer but the size of the focus is the major limi-
tation [12].
　Iczkowski reported that the incidence of ASAP on the ba-
sis of their most recent study was 197 (3.3%) of 6,026 men 
undergoing prostate biopsy [12]; previous studies reported 
incidences of 1.5% to 9.0% [13,14]. Several studies have 
demonstrated that this diagnosis is predictive of malig-
nancy in a subsequent biopsy specimen in 34% to 60% of 
cases [3,4]. Consequently, a repeat biopsy is recommended 
in cases of initial ASAP diagnosis.
　ASAP has been subclassified according to degree of sus-
picion for prostate cancer by several investigators. Chan 
and Epstein found cancer in 61% of patients with atypical 
biopsy favoring a cancer versus 33% of patients with atyp-
ical biopsy favoring a benign process [15]. However, 
Scattoni et al suggested that the subclassification of lesions 
into ASAP highly suspicious for cancer and ASAP favoring 
a benign diagnosis was not clinically useful, and they men-
tioned that the stratification scheme is too subjective to be 
reproducible, even among expert diagnosticians [7].
　Immunostains with 34βE12 and p63 can aid in the inves-
tigation of ASAP, but immunohistochemically negative 
patterns are not diagnostic of prostate cancer (false-neg-
ative staining) [16]. Therefore, a positive marker such as 
alpha-methylacyl coenzyme A racemase (AMACR/P504S) 
has also been used. AMACR is strongly and diffusely pos-
itive in 97% to 100% of prostate cancers and can convert 
atypical foci to cancer in approximately 10% of cases 
[17-19]. However, staining with AMACR is not an error- 
free method because of positivity in 8% of 12% of benign 
glands [20,21].
　The evidence for predictors of prostate cancer after an in-
itial diagnosis of ASAP is contradictory and uncertain. 
Iczkowski et al found that neither age, serum PSA, digital 
rectal examination (DRE), number of positive foci, nor his-
tological findings was predictive of cancer [5]. Ebstein and 
Herawi also reported that no clinical or pathological fea-
tures contributed to or predicted prostate cancer [6]. 
However, Park et al reported that DRE and patient age 
were independent predictors of cancer in patients with 
‘atypia’ [9]. Borboroglu et al showed that PSAV was the only 
significant predictor of positive repeat biopsy [8], whereas 
Scattoni et al claimed prostate volume and HGPIN togeth-
er with ASAP were the only predictive factors in prostate 
cancer detection [7]. Mearini et al commented that the 
free/total PSA ratio and prostate volume seemed to be in-
dependent predictors of prostate cancer at rebiopsy and 
that the clinical value of PSAD in the larger prostate gland 
is altered by the BPH component, which prevails over the 
tumor [1]. Scattoni et al and Ficarra et al suggested that 
the lower rate of prostate cancer in larger prostate glands 
could be due to sampling error [7,22]. In our study, PSAD, 
PSAV, and TPV were significant variables predicting can-
cer detection in patients with ASAP in the multivariate 
analysis, even though TZV was also a significant factor in 
the univariate analysis.
　Brausi et al found that 100% of 25 patients with isolated 
ASAP who underwent radical prostatectomy had cancer. 
Those authors suggested that immediate radical prosta-
tectomy may be the treatment of choice for young patients 
with ASAP [23]. However, performing radical prostatec-
tomy in patients diagnosed as having ASAP is not accep-
table clinical practice in most countries. Ebstein and 
Herawi, Scardino recommend that all men with ASAP un-
dergo rebiopsy within 3 to 6 months, irrespective of fol-
low-up PSA values [6,24].
　However, the most useful rebiopsy strategy is contro-
versial. Allen et al reported that prostate cancer was de-
tected in 84.8% of cases at either the same sextant site as 
the previous biopsy, at adjacent ipsilateral sites, or at ad-
jacent contralateral sites (47.8% of the cancer was detected 
in the same sextant site) and recommended that 3 cores 
should be sampled from the site of the initial atypical site, 
3 cores from the adjacent ipsilateral and adjacent con-
tralateral sites, and 1 core from other sextant sites [25]. On 
the other hand, Scattoni et al found a precise spatial con-
cordance between ASAP and cancer in only 33% of the cases Korean J Urol 2010;51:752-756
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in a multisite scheme study, which was not statistically dif-
ferent from the probability of finding cancer in adjacent 
sites or in nonadjacent sites. They reported that 12 cores 
might not be sufficient to correctly sample prostate glands 
larger than 50 ml in which ASAP is present [7]. According 
to our study, the TPV of the cancer group was smaller than 
that of the noncancer group. Therefore, we suggest that pa-
tients diagnosed as having ASAP should undergo more ex-
tended repeat biopsy with increasing biopsy cores in pa-
tients with large prostate volumes.
　Several limitations to our study exist. (i) Immunohisto-
chemical stains with high molecular weight cytokeratin 
(34βE12) and p63 were performed in our institution, but 
stain with AMACR could not be performed for all patients 
because it was introduced in the middle of our investigation 
period. (ii) A special protocol for repeat biopsy could not be 
established because our investigation was a retrospective 
study. At the repeat biopsy, the number of needle biopsy 
cores (6 cores in patients with prostate volume less than 
30 ml and 12 cores in patients with prostate volume of 30 
ml or more) was not different from that of the initial biopsy 
cores, although extended biopsy with additional biopsy is 
appropriate in initial ASAP patients. Although we did not 
intend this, these biopsy strategies reinforced our argu-
ment of more extended repeat biopsy in patients with a 
large prostate volume, because men with large volumes 
showed a lower incidence of cancer detection despite these 
strategies. (iii) Although some authors have suggested that 
the free/total PSA ratio and prostate volume seem to be in-
dependent predictors of prostate cancer at rebiopsy [1], we 
excluded the free/total PSA ratio from the clinical factors 
in our study because free PSA was not routinely examined 
for all patients.
CONCLUSIONS
PSAD, PSAV, and TPV were significant predictive factors 
of a diagnosis of prostate cancer at a repeat biopsy in men 
with an initial diagnosis of ASAP. PSAD and PSAV were 
higher and TPV was smaller in the cancer group than in 
the noncancer group. Although repeat biopsy is necessary 
within 3 to 6 months, irrespective of PSA values, the follow- 
up of PSA may help to estimate the probability of cancer.
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